Connecting via Winsock to STN

Welcome to STN International! Enter x:x

L* * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:19:04 ON 01 JUL 2009

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\10533081.str





chain nodes :
22 24 25 26 27 28 29 30 31 32
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
chain bonds :
2-25 5-24 7-22 8-26 12-22 15-27 21-31 27-28 28-29 28-32 29-30 30-31
ring bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 11-12 11-16 12-13 13-14
 14-15 15-16 17-18 17-21 18-19 19-20 20-21

exact/norm bonds :
7-22 12-22 15-27 27-28 28-29 28-32
exact bonds :
2-25 5-24 8-26 17-18 17-21 18-19 19-20 20-21 21-31 29-30 30-31
normalized bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16
isolated ring systems :
containing 1 : 11 : 17 :

G1:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sam
SAMPLE SEARCH INITIATED 14:20:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       19 TO ITERATE

100.0% PROCESSED       19 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          119 TO      641
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:20:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      313 TO ITERATE

100.0% PROCESSED      313 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

L3            3 SEA SSS FUL L1

=> file caplus

=> s l3
L4           1 L3

=> d ibib abs hitstr

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2004:390229  CAPLUS
DOCUMENT NUMBER:         140:406748
TITLE:                   Preparation of quinoline derivatives and quinazoline
                         derivatives inhibiting autophosphorylation of Flt3 and
                         medicinal compositions containing the same
INVENTOR(S):             Hirai, Hisamaru; Miwa, Atsushi; Yoshino, Tetsuya;
                         Kurokawa, Mineo
PATENT ASSIGNEE(S):      Kirin Beer Kabushiki Kaisha, Japan; Hirai, Naoko
SOURCE:                  PCT Int. Appl., 118 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                Japanese
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2004039782        A1    20040513    WO 2003-JP13848        20031029
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
```

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003280599	A1	20040525	AU 2003-280599		20031029
EP 1566379	A1	20050824	EP 2003-769958		20031029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 20080207617	A1	20080828	US 2006-533081		20061109
PRIORITY APPLN. INFO.:			JP 2002-314670	A	20021029
			WO 2003-JP13848	W	20031029

OTHER SOURCE(S): MARPAT 140:406748

GI



I

AB Disclosed is a medicinal composition to be used in preventing or treating diseases which can be effectively treated or prevented by inhibiting autophosphorylation of Flt3, comprising a compound represented by the following general formula (I) or pharmaceutically acceptable salts thereof or solvates of the same [wherein X = CH, N; Z = O, S; R1, R2, R3 = H, OH, halo, NO2, cyano, CHO, or each optionally substituted NH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-4 alkyl-carbonyl, or CONH2; R4 = H; R5 = R6 = R7 = R8 = H, or 1 or 2 number of R5-R8 = halo, C1-4 alkyl, C1-4 alkoxy, NO2, NH2, OH and all the others = H; R9 = (a) saturated 3- to 9-membered carbocyclyl optionally substituted by 1-3 number of C1-4 alkyl or (b) C1-4 alkyl substituted by C1-4 alkoxy, 5- or 6-membered heterocyclyl, each (un)substituted saturated 3- to 9-membered carbocyclyl, iso-Pr, tert-Bu, or NH2]. The diseases which can be effectively treated by inhibiting autophosphorylation of Flt3 include hematopoietic malignant tumor, in particular acute myelocytic leukemia or bone marrow neoplastic abnormality syndrome. Thus, 2 g 4-[(6,7-dimethoxy-4-quinolinyl)oxy]aniline was dissolved in 100 mL CHCl3, treated dropwise with a solution of 2 mL Et3N and 1 g triphosgene in 4 mL CHCl3, stirred at room temperature for 30 min, treated with 750 mg 3,3-dimethylbutylamine, and stirred at room temperature for 5 h to give, after workup and silica gel chromatog., N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(3,3-dimethylbutyl)urea (II). II.HCl and N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-3-fluorophenyl]-N'-(3,3-dimethylbutyl)urea hydrochloride showed IC50 of 2 and <1 nM, resp., for inhibiting the autophosphorylation of MV4-11 human leukemia cell.

IT 688309-27-5P 688309-49-1P 688309-61-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline and quinazoline derivs. as inhibitors of autophosphorylation of FMS-like tyrosine kinase 3 (Flt3) for treatment or preparation of hematopoietic malignant tumor)

RN 688309-27-5 CAPLUS
CN Urea, N-(2-cyclopentylethyl)-N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-3-fluorophenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 688309-49-1 CAPLUS
CN Urea, N-(2-cyclopentylethyl)-N'-[3-fluoro-4-[[6-methoxy-7-[2-(1-piperidinyl)ethoxy]-4-quinolinyl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 688309-61-7 CAPLUS
CN Urea, N-(2-cyclopentylethyl)-N'-[2-fluoro-4-[[6-methoxy-7-[2-(1-piperidinyl)ethoxy]-4-quinolinyl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file marpat

=> s l3 full
FULL SEARCH INITIATED 14:20:25 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 6395 TO ITERATE

100.0% PROCESSED 6395 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.05

L5 2 SEA SSS FUL L1

=> d his

(FILE 'HOME' ENTERED AT 14:19:04 ON 01 JUL 2009)

```
     FILE 'REGISTRY' ENTERED AT 14:19:45 ON 01 JUL 2009
L1              STRUCTURE UPLOADED
L2            0 S L1 SAM
L3            3 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 14:20:10 ON 01 JUL 2009
L4            1 S L3

     FILE 'MARPAT' ENTERED AT 14:20:19 ON 01 JUL 2009
L5            2 S L3 FULL

=> d ibib abs fqhit 1-2

L5   ANSWER 1 OF 2  MARPAT  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         140:406748  MARPAT
TITLE:                    Preparation of quinoline derivatives and quinazoline
                          derivatives inhibiting autophosphorylation of Flt3 and
                          medicinal compositions containing the same
INVENTOR(S):              Hirai, Hisamaru; Miwa, Atsushi; Yoshino, Tetsuya;
                          Kurokawa, Mineo
PATENT ASSIGNEE(S):       Kirin Beer Kabushiki Kaisha, Japan; Hirai, Naoko
SOURCE:                   PCT Int. Appl., 118 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2004039782      A1   20040513       WO 2003-JP13848  20031029
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003280599      A1   20040525       AU 2003-280599   20031029
     EP 1566379         A1   20050824       EP 2003-769958   20031029
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     US 20080207617     A1   20080828       US 2006-533081   20061109
PRIORITY APPLN. INFO.:                     JP 2002-314670   20021029
                                           WO 2003-JP13848  20031029
GI
```



I

AB Disclosed is a medicinal composition to be used in preventing or treating diseases which can be effectively treated or prevented by inhibiting autophosphorylation of Flt3, comprising a compound represented by the following general formula (I) or pharmaceutically acceptable salts thereof or solvates of the same [wherein X = CH, N; Z = O, S; R1, R2, R3 = H, OH, halo, NO2, cyano, CHO, or each optionally substituted NH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-4 alkyl-carbonyl, or CONH2; R4 = H; R5 = R6 = R7 = R8 = H, or 1 or 2 number of R5-R8 = halo, C1-4 alkyl, C1-4 alkoxy, NO2, NH2, OH and all the others = H; R9 = (a) saturated 3- to 9-membered carbocyclyl optionally substituted by 1-3 number of C1-4 alkyl or (b) C1-4 alkyl substituted by C1-4 alkoxy, 5- or 6-membered heterocyclyl, each (un)substituted saturated 3- to 9-membered carbocyclyl, iso-Pr, tert-Bu, or NH2]. The diseases which can be effectively treated by inhibiting autophosphorylation of Flt3 include hematopoietic malignant tumor, in particular acute myelocytic leukemia or bone marrow neoplastic abnormality syndrome. Thus, 2 g 4-[(6,7-dimethoxy-4-quinolinyl)oxy]aniline was dissolved in 100 mL CHCl3, treated dropwise with a solution of 2 mL Et3N and 1 g triphosgene in 4 mL CHCl3, stirred at room temperature for 30 min, treated with 750 mg 3,3-dimethylbutylamine, and stirred at room temperature for 5 h to give, after workup and silica gel chromatog., N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(3,3-dimethylbutyl)urea (II). II.HCl and N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-3-fluorophenyl]-N'-(3,3-dimethylbutyl)urea hydrochloride showed IC50 of 2 and <1 nM, resp., for inhibiting the autophosphorylation of MV4-11 human leukemia cell.

MSTR 1



G1 = CH
G2 = O
G13 = 89



G32 = (2-4) CH2
Patent location: claim 1
Note: or pharmaceutically acceptable salts or solvates
Note: additional ring formation also claimed

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 140:357353 MARPAT
TITLE: Preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents
INVENTOR(S): King, Bryan W.; Sheppeck, James; Gilmore, John L.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032846	A2	20040422	WO 2003-US31537	20031003
WO 2004032846	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003284001	A1	20040504	AU 2003-284001	20031003
US 20040116491	A1	20040617	US 2003-678331	20031003
US 7074810	B2	20060711		
EP 1558581	A2	20050803	EP 2003-776228	20031003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-416709P	20021007
			WO 2003-US31537	20031003

GI



AB The present application describes novel hydantoin derivs. (shown as I; A = O, S; L-R11 represents a very large variety of substituents and is defined in the claims; e.g. II) or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof. Some examples of I exhibit Ki's <10 μM but individual data are not presented. Although the methods of preparation are not claimed, 37 example prepns. are included. For example, II was prepared in 4 steps (100, 66, 73 and 82%, resp.) starting with condensation of Et 4-aminobutyrate hydrochloride with 4-(2-methylquinolin-4-ylmethoxy)benzoyl chloride hydrochloride followed by base hydrolysis to the acid, followed by hydrazide formation with thiosemicarbazide followed by cyclization.

MSTR 1



G2 = 31-4 32-10



G10 = 108

108 

G12 = carbon chain <containing 1 or more C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd.)
G13 = 89-10 90-41

HN——C(O)
89 90

G14 = bond
G15 = NH (opt. substd.)
G16 = phenylene (opt. substd.)
G17 = O
G18 = bond
G19 = quinolinyl (opt. substd. by G23)
Patent location: claim 1
Note: or pharmaceutically acceptable salts
Note: additional ring formation also claimed
Note: substitution is restricted
Stereochemistry: or stereoisomers

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:19:04 ON 01 JUL 2009)

FILE 'REGISTRY' ENTERED AT 14:19:45 ON 01 JUL 2009
L1 STRUCTURE UPLOADED
L2 0 S L1 SAM
L3 3 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:20:10 ON 01 JUL 2009
L4 1 S L3

FILE 'MARPAT' ENTERED AT 14:20:19 ON 01 JUL 2009
L5 2 S L3 FULL

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y
TERNATIONAL LOGOFF AT 14:21:59 ON 01 JUL 2009